How the Chemical Properties of GBCAs Influence Their Safety Profiles In Vivo
Open Access
Abstract
The extracellular class of gadolinium-based contrast agents (GBCAs) is an essential tool for clinical diagnosis and disease management. In order to better understand the issues associated with GBCA administration and gadolinium retention and deposition in the human brain, the chemical properties of GBCAs such as relative thermodynamic and kinetic stabilities and their likelihood of forming gadolinium deposits in vivo will be reviewed. The chemical form of gadolinium causing the hyperintensity is an open question. On the basis of estimates of total gadolinium concentration present, it is highly unlikely that the intact chelate is causing the T1 hyperintensities observed in the human brain. Although it is possible that there is a water-soluble form of gadolinium that has high relaxitvity present, our experience indicates that the insoluble gadolinium-based agents/salts could have high relaxivities on the surface of the solid due to higher water access. This review assesses the safety of GBCAs from a chemical point of view based on their thermodynamic and kinetic properties, discusses how these properties influence in vivo behavior, and highlights some clinical implications regarding the development of future imaging agents.Keywords
Funding Information
- National Institute of Child Health and Human Development (K25HD104004)
- National Institute of Biomedical Imaging and Bioengineering (R21EB030765, R21EB031367, P41EB015908)
This publication has 147 references indexed in Scilit:
- Quantification of gadolinium in fresh skin and serum samples from patients with nephrogenic systemic fibrosisJournal of the American Academy of Dermatology, 2011
- Pathophysiology of nephrogenic systemic fibrosis: A review of experimental dataWorld Journal of Radiology, 2010
- Incorporation of excess gadolinium into human bone from medical contrast agentsMetallomics, 2009
- Efficiency, thermodynamic and kinetic stability of marketed gadolinium chelates and their possible clinical consequences: a critical reviewBioMetals, 2008
- Synthesis and Characterization of DOTA‐(amide)4 Derivatives: Equilibrium and Kinetic Behavior of Their Lanthanide(III) ComplexesEuropean Journal of Inorganic Chemistry, 2007
- Equilibrium and Formation/Dissociation Kinetics of Some LnIIIPCTA ComplexesInorganic Chemistry, 2006
- Comparison of Gd(DTPA-BMA) (Omniscan) Versus Gd(HP-DO3A) (ProHance) Relative to Gadolinium Retention in Human Bone Tissue by Inductively Coupled Plasma Mass SpectroscopyInvestigative Radiology, 2006
- Thermodynamic and Kinetic Studies of Lanthanide(III) Complexes with H5do3ap (1,4,7,10-Tetraazacyclododecane-1,4,7-triacetic-10-(methylphosphonic Acid)), a Monophosphonate Analogue of H4dotaCollection of Czechoslovak Chemical Communications, 2005
- Scleromyxoedema-like cutaneous diseases in renal-dialysis patientsThe Lancet, 2000
- Biodistribution of Radiolabeled, Formulated Gadopentetate, Gadoteridol, Gadoterate, and Gadodiamide in Mice and RatsInvestigative Radiology, 1995